Novo Nordisk CEO Agrees to Testify at Senate Hearing After Sanders’ Subpoena Threat

Novo Nordisk California/iStock, hapabapa

Pictured: Novo Nordisk’s office in Fremont, California/iStock, hapabapa

Novo Nordisk CEO Lars Jørgensen has agreed to testify before the Senate Health, Education, Labor and Pensions Committee regarding the prices of the pharma’s top-selling semaglutide brands Ozempic and Wegovy, according to Sen. Bernie Sanders (I-Vt.).

Jørgensen will appear before the committee in a hearing dedicated to what Sanders calls the “outrageously high prices” of Ozempic and Wegovy in the U.S. The hearing is scheduled for early September 2024, though no exact date has been given yet.

Sanders, who is chair of the Health, Education, Labor and Pensions Committee, in a statement on Friday said that he “enjoyed” his conversation with Jørgensen, thanking him for “agreeing to voluntarily testify” at the hearing.

Last week, Sanders threatened to subpoena Novo Nordisk President Doug Langa to provide testimony about his company’s pricing for Ozempic…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks